EcoDrugPlus

Endothelin Receptor Type Ab

Ensembl ID : ENSMMDG00005002420
Gene Symbol: EDNRAB
1 Cross references
197 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSMMDG00005023374
Gene Symbol: EDNRB
1 Cross references
196 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSMMDG00005023913
Gene Symbol: EDNRB
3 Cross references
196 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSMMDG00005021370
Gene Symbol: EZH2
3 Cross references
229 Possible Orthologues:

Eph Receptor B4b

Ensembl ID : ENSMMDG00005017692
Gene Symbol: EPHB4B
1 Cross references
169 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSMMDG00005022868
Gene Symbol: EGFRA
1 Cross references
212 Possible Orthologues:

Epoxide Hydrolase 2

Ensembl ID : ENSMMDG00005006646
Gene Symbol: EPHX2
2 Cross references
203 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSMMDG00005014529
Gene Symbol: LOC115372375
3 Cross references
209 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSMMDG00005024319
Gene Symbol: ERBB2
1 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSMMDG00005021353
Gene Symbol: ERBB3
1 Cross references
211 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSMMDG00005021557
Gene Symbol: ERBB4
1 Cross references
47 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSMMDG00005000605
Gene Symbol: ERBB4
1 Cross references
229 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).